Stockscreener 앱 받기
0.904
0.46%
-0.0042
시간 외 거래:
.89
-0.014
-1.55%
전일 마감가:
$0.9082
열려 있는:
$0.9215
하루 거래량:
915.16K
Relative Volume:
0.63
시가총액:
$107.90M
수익:
-
순이익/손실:
$-25.91M
주가수익비율:
-3.5916
EPS:
-0.2517
순현금흐름:
$-22.73M
1주 성능:
+14.10%
1개월 성능:
+6.33%
6개월 성능:
-7.09%
1년 성능:
-20.00%
1일 변동 폭
$0.885
$0.94
1주일 범위
$0.80
$1.08
52주 변동 폭
$0.77
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
명칭
Oncolytics Biotech Inc
전화
(403) 670-7377
주소
SUITE 325, 4350 EXECUTIVE DRIVE, SAN DIEGO, AB
Compare ONCY vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.904 | 110.87M | 0 | -25.91M | -22.73M | -0.2517 |
VRTX
Vertex Pharmaceuticals Inc
|
477.08 | 121.89B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.45 | 69.52B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
862.93 | 54.49B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
184.44 | 39.11B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
279.14 | 38.46B | 4.29B | 577.22M | 641.34M | 4.2086 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-13 | 개시 | Lake Street | Buy |
| 2022-10-06 | 개시 | Maxim Group | Buy |
| 2021-02-17 | 개시 | H.C. Wainwright | Buy |
Oncolytics Biotech Inc 주식(ONCY)의 최신 뉴스
Oncolytics Biotech Shares Rise on FDA Meeting Plan, Trial Progress in Colorectal Cancer - Moomoo
H.C. Wainwright reiterates Oncolytics Biotech stock rating on trial progress By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Oncolytics Biotech stock rating on trial progress - Investing.com
Stocks in play: Oncolytics Biotech Inc - Barchart.com
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics Biotech Shares Climb Ahead of Planned FDA Meeting on REO 033 Trial (ONCY) - Yahoo Finance
Oncolytics (ONCY) Updates on REO 033 Clinical Study Progress - GuruFocus
Oncolytics Biotech stock jumps on FDA meeting plans for trial - Investing.com
Oncolytics advances colorectal cancer trial, plans FDA meeting By Investing.com - Investing.com India
Oncolytics advances colorectal cancer trial, plans FDA meeting - Investing.com
Cancer trial using pelareorep seeks FDA input on path to possible approval - Stock Titan
ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study - Stocktwits
Oncolytics Biotech Inc (ONCY) Institutional Confidence - TradingKey
Oncolytics Biotech (NASDAQ:ONCY) Shares Up 16.1%What's Next? - MarketBeat
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Oncolytics Biotech Inc. Replaces Ernst & Young with Baker Tilly as Independent Auditor in 2026 Corporate Restructuring – Minichart - Minichart
Oncolytics Biotech (ONCY) replaces Ernst & Young with Baker Tilly as 2026 auditor - Stock Titan
NMAD Stock Price and Chart — NASDAQ:NMAD - TradingView
ONCY News | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
ONCY Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of Oncolytics Biotech Inc. – NASDAQ:ONCY - TradingView
Price to sales forward of Oncolytics Biotech Inc. – NASDAQ:ONCY - TradingView
Oncolytics Biotech Inc (ONCY) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oncolytics Biotech Inc (ONCY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Oncolytics Biotech | 8-K: Current report - Moomoo
Oncolytics Biotech StockWeekly review and sector backdrop - AD HOC NEWS
Oncolytics Biotech | F-10POS: Others - Moomoo
Oncolytics Biotech Inc (ONCY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oncolytics Biotech Inc (ONCY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oncolytics Biotech Inc (ONCY) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oncolytics Biotech® to Host Conference Call to Discuss First Qua - GuruFocus
Oncolytics Biotech Inc (ONCY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oncolytics Biotech Inc (ONCY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Oncolytics Biotech Inc (ONCY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oncolytics Biotech Secures New Pelareorep Manufacturing Patent - The Globe and Mail
Oncolytics (ONCY) Secures New Patent for Pelareorep Manufacturin - GuruFocus
ONCY Stock Surged Today – Here’s What Securing A Key Immunotherapy Patent Means For Oncolytics - Yahoo Finance
Oncolytics receives U.S. patent for pelareorep manufacturing By Investing.com - Investing.com South Africa
Oncolytics Gets US Patent for Pelareorep Manufacturing Process - marketscreener.com
Oncolytics receives U.S. patent for pelareorep manufacturing - Investing.com
Oncolytics Biotech Announces New US Patent For Pelareorep Manufacturing Process - TradingView
Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044 - The Manila Times
New pelareorep patent extends Oncolytics Biotech (Nasdaq: ONCY) IP to 2044 - Stock Titan
Oncolytics Builds a 20-Year Patent Fortress for Its Cancer Immunotherapy - BriefGlance
Oncolytics Biotech® to Participate in a Panel Presentation at Ca - GuruFocus
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY) - The Globe and Mail
JonesTrading Maintains Oncolytics Biotech(ONCY.US) With Hold Rating - Moomoo
Oncolytics Biotech(R) Reports 2019 Third Quarter Financial Results and Operational Highlights - ACCESS Newswire
ONCY: Promising GI cancer data and new patent strategies position pelareorep for major milestones - TradingView
Oncolytics Biotech (ONCY) Jefferies Global Healthcare Conference 2026 Summary - Quartr
ONCY: Pivotal data for a novel IV oncolytic virus in GI cancers expected by year-end - TradingView
Oncolytics Biotech Inc (ONCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Oncolytics Biotech Inc 주식 (ONCY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kelly Jared | Chief Executive Officer |
Mar 12 '26 |
Buy |
0.96 |
5,050 |
4,848 |
114,050 |
| Kelly Jared | Chief Executive Officer |
Feb 12 '26 |
Buy |
0.84 |
29,500 |
24,839 |
109,000 |
| Kelly Jared | Chief Executive Officer |
Feb 11 '26 |
Buy |
0.84 |
5,600 |
4,682 |
79,500 |
| Look Kirk | Chief Financial Officer |
Feb 12 '26 |
Buy |
0.84 |
12,000 |
10,104 |
287,515 |
| Pisano Wayne | Director |
Feb 12 '26 |
Buy |
0.84 |
30,000 |
25,338 |
492,414 |
| Heineman Thomas Charles | Chief Medical Officer |
Feb 12 '26 |
Buy |
0.83 |
12,132 |
10,033 |
282,818 |
| Brown Deborah Margaret | Director |
Feb 12 '26 |
Buy |
0.85 |
25,000 |
21,240 |
109,851 |
| Hagerman Allison | VP, Product Development |
Feb 12 '26 |
Buy |
0.83 |
10,000 |
8,298 |
115,059 |
| Seizinger Bernd R. | Director |
Feb 11 '26 |
Buy |
0.83 |
60,000 |
49,590 |
526,991 |
| Seizinger Bernd R. | Director |
Feb 12 '26 |
Buy |
0.85 |
40,000 |
33,864 |
566,991 |
0.27%
1.15%
자본화:
|
볼륨(24시간):